⚠️Good news! 1st peer-reviewed report of a #coronavirus vaccine study shows promising results in 108 participants:
▶️No serious safety signals
▶️78% in low-dose, 92% in mid-dose, and 100% in high-dose groups developed neutralizing antibodies or a T-cell response to #SARSCoV2.
▶️No serious safety signals
▶️78% in low-dose, 92% in mid-dose, and 100% in high-dose groups developed neutralizing antibodies or a T-cell response to #SARSCoV2.
Based on studies of those who recovered from #COVID19, the spike protein on the surface of the #coronavirus is a key target of the immune system.
This vaccine uses an adenovirus—it cannot replicate but expresses the #coronavirus spike protein.
@TheLancet
thelancet.com/action/showPdf…
This vaccine uses an adenovirus—it cannot replicate but expresses the #coronavirus spike protein.
@TheLancet
thelancet.com/action/showPdf…
This report from a phase 1 study is encouraging, but there’s still a long way to go. That said, we now have MULTIPLE #vaccine shots on goal, and I’m increasingly optimistic that we will eventually have an effective #coronavirus vaccine.🤞🏼
#COVID19
#COVID19
